While the survival rates of women with estrogen receptor-positive and HER2-positive breast cancers have increased with the development of tamoxifen and herceptin, respectively [38,39], TNBCs retain the lowest 5-year survival rates [1]. This evidence concerns the gene ERBB2 and breast carcinoma.